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Stuttering is a complex speech disorder. There are two forms of stuttering: developmental stuttering and acquired stuttering.
Developmental stuttering is a disorder of early childhood but acquired stuttering can develop at any age. Some medications
can induce or deteriorate stuttering as an adverse effect. There are several reports of stuttering due to psychotropic drugs.
Memantine, a glutamate antagonist used in the treatment of Alzheimer’s disease, has also been studied for the treatment of
autism spectrum disorders. This report presents deterioration of stuttering and speech problem in two children with autistic
disorder who were receiving memantine. Based on our knowledge, this is the first time these adverse drug reactions have
been attributed to memantine. In conclusion clinicians should consider that speech problems including stuttering may be
due to the consumption of memantine, especially, in children may be a side effect of memantine especially in children.
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Stuttering is a neurodevelopmental disorder which inter-
feres with academic and/ or occupational achievement
as well as social communication.
The International Classification of Diseases version 10
(ICD-10) categorized stuttering as a behavioral and emo-
tional disorder, and coded as F98.5 with this depiction:
“Speech that is characterized by frequent repetition or
prolongation of sounds or syllables or words, or by
frequent hesitations or pauses that disrupt the rhythmic
flow of speech. It should be classified as a disorder only if
its severity is such as to markedly disturb the fluency of
speech”.
Diagnostic and Statistical Manual of Mental Disorders,
fourth Edition, Text Revision (DSM-IV-TR) described
stuttering as frequent occurrences of one or more of the
following: sound and syllable repetitions, sound prolon-
gations, interjections, broken words, audible or silent
blocking, circumlocutions, words produced with an ex-
cess of physical tension, and monosyllabic whole word
repetitions.
Developmental stuttering, the most common type of
stuttering, is a disorder of early childhood with mean* Correspondence: mmppg@yahoo.com
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Ambrose, in a recent review article approximated the
life-time prevalence of stuttering as 0.75% and its life
time incidence has been reported to be between 5 to 8%.
This study also reported that the prevalence of this
disorder is a little higher among men at the onset of this
disorder that what is seen in females. “The smaller polar-
ity of affected males versus females near the time of
onset as compared with the polarity at more advanced
ages suggests that recovery from stuttering is consider-
ably more frequent in girls than in boys” [1]. Recovery
from developmental stuttering without any intervention
occurs in about 75% of persons [2]. Acquired stuttering
which can occur at any age is resulted from secondary
causes such as drugs, head trauma, stroke, and brain
tumors [2-4]. Most published reports of drug induced
stuttering have noted psychotropics such as bupropion
[5], clozapine [6,7], topiramate [8], lithium [4], tricyclic
antidepressants [5,9], phenothiazines [5,9,10], selective
serotonin reuptake inhibitors (sertraline and fluoxetine)
[5,9], risperidone [11], olanzapine [7], stimulants [9,10,12]
as responsible agents.
Autistic disorder is a subtype of pervasive develop-
mental disorders (PDDs). The core symptoms of autism
include impairments in social interactions, verbal and
nonverbal communication skills and stereotyped actions
and tendencies [13]. An autistic patient that is able toCentral Ltd. This is an Open Access article distributed under the terms of the
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PDDs patients have structural language disturbances or
Functional deficits [14]. Stuttering is one of the speech
disorders that may occur in PDDs patients [15,16].
Memantine, an antagonist of N-Methyl-D-Aspartate
(NMDA) receptors of glutamate [17], was approved for
the treatment of moderate to severe Alzheimer’s disease.
It has been used in some patients with PDDs [18-21].
Our report includes two cases with speech difficulty
and deterioration of stuttering caused by memantine




A 9-year-old boy, with a 5 years history of autistic disorder,
was referred to one of the author’s child and adolescent
psychiatric clinic (J.A.) for the management of his condi-
tion. His parents report his developmental stuttering as
sound repetition and sound prolongation on first and mid-
dle vowels since age 4. At the time the child psychiatrist
prescribed risperidone (an atypical antipsychotic); however,
the parents refused giving this medication to their son
because of their general worries about the side effects
of drugs. Over time, the parents came to conclusion
that they need to seek professional psychiatric help for
their child’s behavioral and educational difficulties.
After a thorough assessment of the patient, memantine
5 mg per day was started and increased to 7.5 mg per
day after 7 days. The dose was increased to 10 mg per
day once again after 1 week. At the beginning of the
third week, he encountered deterioration of stuttering
and difficulty for starting to speak. His parents ex-
plained that the child could only start to speak after a
deep and audible breath. Otherwise, he was not able to
talk. This problem was only noted at the beginning of
the patient’s speech and vanished after a while. No other
new stressful or deteriorating condition was thought to ag-
gravate his speech difficulty. Since memantine was the
only drug he was consuming, it was decided to reduce the
dose of memantine to 7.5 mg per day. Several days after
this dose reduction, the patient did not need to take such
a deep, audible breath before speaking. However, the de-
teriorating symptoms of stuttering caused so much dis-
tress for the patient and his family that the treating
psychiatrist decided to taper down and finally to discon-
tinue memantine. Three weeks after discontinuation of
memantine, aggravated stuttering was reduced to its base-
line. Then, risperidone was prescribed for the manage-
ment of autism.
Case2
A 4-year-old boy with a history of autism was referred
to one of the author’s (M.T.) private psychiatrist officefor management of his symptoms. There was no reported
comorbidity. Patient’s speech was fluent despite having
difficulties in expressing himself. He previously received
risperidone for the treatment of autism but he had a par-
tial response to this medication. The patient was started
on memantine 2.5 mg per day that was continued for
1 week and then increased to 5 mg per day. Similar to the
first case, the child could only start to speak after a deep
and audible breath. Otherwise, he was not able to talk.
This problem was only noted at the beginning of speech
and vanished after a while. Due to the fact that risperidone
was discontinued 3 weeks prior to the initiation of
memantine and the patient was not receiving any other
medication, the new adverse effect was attributed to
memantine. Since this difficulty was tolerable, memantine
was continued at the same dose and was gradually
increased to 7.5 mg per day. Interestingly, the speech diffi-
culty was completely relieved despite continuation of
memantine.
Discussion
Memantine is an uncompetitive antagonist of NMDA
receptor of glutamate. It has been used in several trials
for the treatment of PDDs [18-21]. Interestingly, there
are limited reports of stuttering development with glu-
tamate antagonists such as lamotrigine and topiramate
[8,22,23]. To the authors’ knowledge, there has been no
previous report of stuttering induced or deteriorated by
memantine use in children or adults. It should be noted
that aphasia is one of the reported adverse effects of this
medication [24]. However, this drug has been studied in
the management of chronic post-stroke aphasia and
showed improvement in the severity of this side effect
[25]. Therefore, due to scant information on the causal-
ity of the relationship between memantine and aphasia,
performing further studies in this area seem to be neces-
sary to investigate this relationship.
The two patients in this report did not face any new
stressful situations or conditions while under observa-
tion. Since both patients were only on memantine when
their speech difficulties occurred, this drug was believed
to be responsible for these adverse effects. Based on
Naranjo adverse drug reaction probability scale, respon-
sibility of memantine for occurrence of mentioned side
effects was estimated as probable.
Although role of several neurotransmitters such as
Gamma Amino Butyric Acid (GABA), serotonin and
dopamine have been proposed in the pathogenesis of
stuttering [2,26], it seems that the effects of dopamine
are more prominent. It should be noted that the benefi-
cial effects of anti-dopaminergic drugs such as risperi-
done, aripiprazole and olanzapine in the treatment of
stuttering may confirm the role of dopamine in this
disorder [2,27,28]. Additionally, due to the effects of
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a role for this neurotransmitter in the pathogenesis of some
speech difficulties.
Conclusion
The two cases presented in this report suggest that
memantine may induce or exacerbate stuttering or cause
difficulties in initiating speech in patients diagnosed with
autism. The authors recommend that all clinicians
should be aware of these bothersome speech-related side
effects of memantine when deciding to prescribe this
medication.
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